New roles for IGF binding proteins

Endocrinologist

Volumn 9, Issue 6, 1999, Pages 438-450

  Ferry Jr , Robert J ^a   Liu, Bingrong ^a   Cohen, Pinchas ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN;

BINDING AFFINITY; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; GENE CONTROL; GENE FUNCTION; PROTEIN BINDING; REVIEW; SOMATIC CELL;

EID: 2442727511     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019616-199911000-00006     Document Type: Review

References (168)

1. Mauricio D, Mandrup-Poulsen T: Apoptosis and the pathogenesis of IDDM: a question of life and death. Diabetes 1998; 47: 1537-43.
2. Naitoh J, Witte O, Belldegrun A: The University of California, Los Angeles/Jennifer Jones Simon Foundation symposium on prostate cancer and epithelial cell biology: bringing together basic scientists and clinicians in the fight against advanced prostate cancer. Cancer Res 1998; 58: 2895-900.
3. Baxter RC: Insulin-like growth factor binding proteins in the human circulation, a review. Horm Res 1994; 42: 140-4.
4. Hasegawa T, Cohen P, Rosenfeld RG: Characterization of the insulin-like growth factor axis in TM 3 Leydig cells. Growth Regul 1995; 151-9.
5. Han VK, Matsell DG, Delhanty PJ, Hill DJ, Shimasaki S, Nygard K: IGF-binding protein mRNAs in the human fetus: tissue and cellular distribution of developmental expression. Horm Res 1996; 45: 160-6.
6. Arany E, Afford S, Strain AJ, Winwood PJ, Arthur MJ, Hill DJ: Differential cellular synthesis of insulin-like growth factor binding protein 1 and IGFBP-3 within human liver. J Clin Endocrinol Metab 1994; 79: 1871-6.
7. Chin E, Zhou J, Dai J, Baxter RC, Bondy CA: Cellular localization and regulation of gene expression for components of the insulin-like growth factor ternary binding protein complex. Endocrinology 1994; 134: 2498-504.
8. Villafuerte BC, Koop BL, Pao CI, Gu L, Birdsong GG, Phillips LS: Coculture of primary rat hepatocytes and nonparenchymal cells permits expression of insulin-like growth factor binding protein-3 in vitro. Endocrinology 1994; 134: 2044-50.
9. Cohen P, Rosenfeld RG: The IGF axis. In Human Growth Hormone, Basic and Scientific Aspects, edited by Rosenbloom AL, pp. 43-58. Boca Raton, FL, CRC Press 1995.
10. Rosenfeld RG, Pham H, Cohen P, et al.: Insulin-like growth factor binding proteins and their regulation. Acta Paediatr 1994; 339 (suppl): 154-8.
11. Baxter RC, Binoux MA, Clemmons DR, et al.: Recommendations for nomenclature of the insulin-like growth factor binding protein superfamily. Endocrinology 1998; 139: 4036.
12. Cohen P, Fielder PJ, Hasegawa Y, Frisch H, Giudice LC, Rosenfeld RG: Clinical aspects of insulin-like growth factor binding proteins. Acta Endocrinol 1991; 124(suppl 2): 74-85.
13. Holly JMP, Martin JL: IGFBPs: a review of methodological aspects of their purification, analysis and regulation. Growth Regul 1994; 4(suppl): 20-30.
14. Lamson G, Giudice LC, Rosenfeld RG: Insulin-like growth factor binding proteins: structural and molecular relationships. Growth Factors 1991; 5: 19-28.
15. Underwood LE, Thissen JP, Lemozy S, Ketelslegers JM, Clemmons DR: Hormonal and nutritional regulation of IGF-I and its binding proteins. Hormone Res 1994; 42: 145-51.
16. Shimasaki S, Ling N: Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5, and -6). Prog Growth Factor Res 1991; 3: 243-66.
17. Allander SV, Bajalica S, Larsson C, et al.: Structure and chromosomal localization of human insulin-like growth factor-binding protein genes. Growth Regul 1993; 3: 3-5.
18. Katz LEL, Rosenfeld RG, Cohen P: Clinical significance of insulin-like growth factor binding proteins (IGFBPs). Endocrinologist 1995; 5: 36-43.
19. Martina NA, Kim E, Chitkara U, et al.: Gestational age-dependent expression of insulin-like growth factor-binding protein-1 (IGFBP-1) phosphoisoforms in human extraembryonic cavities, maternal serum, and decidua suggests decidua as the primary source of IGFBP-1 in these fluids during early pregnancy. J Clin Endocrinol Metab 1997; 82: 1894-8.
20. Coverley JA, Baxter RC: Phosphorylation of insulin-like growth factor binding proteins. Mol Cell Endocrinol 1997; 128(1-2): 1-5.
21. Lewitt MS, Saunders H, Cooney GJ, Baxter RC: Effect of human insulin-like growth factor-binding protein-1 on the half-life and action of administered insulin-like growth factor-I in rats J Endocrinol 1993; 136: 253-60.
22. Bar RS, Boes M, Clemmons DR, et al.: Insulin differentially alters transcapillary movement of intravascular IGFBP-1, IGFBP-2 and endothelial cell IGF-binding proteins in the rat heart. Endocrinology 1990; 127: 497-9.
23. Jones JI, Gockerman A, Busby WH Jr, Wright G, Clemmons DR: Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its ArgGly-Asp sequence. Proc Natl Acad Sci USA 1993; 90: 10553-7.
24. Samstein B, Hoimes ML, Fan J, Frost RA, Gelato MC, Lang CH: IL-6 stimulation of insulin-like growth factors binding proteins (IGFBPs) production. Biochem Biophys Res Commun 1996; 228: 611-5.
25. Katz LEL, Satin-Smith MS, Collett-Solberg P, Baker L, Stanley CA, Cohen P: Dual regulation of insulin-like growth factor binding protein-1 levels by insulin and cortisol during fasting. J Clin Endocrinol Metab 1998; 83: 4426-30.
26. Hu M, Robertson DG, Murphy LJ: Growth hormone modulates insulin regulation of hepatic insulin-like growth factor binding protein-1 transcription. Endocrinology 1996; 137: 3702-9.
27. Jousse C, Bruhat A, Ferrara M, Fafournoux P: Physiological concentration of amino acids regulates insulin-like-growth-factor-binding protein 1 expression. Biochem J 1998; 334(Pt 1): 147-53.
28. Katz LEL, Satin-Smith MS, Collett-Solberg P, Thornton PS, Baker L, Stanley CA, et al.: Insulin-like growth factor binding protein-1 levels in the diagnosis of hypoglycemia caused by hyperinsulinism [comment in J Pediatr 1997; 131: 171-3]. J Pediatr 1997; 131: 193-9.
29. Counts DR, Gwirtsman H, Carlsson LM, Lesem M, Cutler GB Jr: The effect of anorexia nervosa and refeeding on growth hormone-binding protein, the insulin-like growth factors (IGFs), and the IGF-binding proteins. J Clin Endocrinol Metab 1992; 75: 762-7.
30. Strasser-Vogel B, Blum WF, Past R, et al.: Insulin-like growth factor (IGF)-I and -II and IGF-binding proteins-1, -2, and -3 in children and adolescents with diabetes mellitus: correlation with metabolic control and height attainment. J Clin Endocrinol Metab 1995; 80: 1207-13.
31. Unterman TG, Oehler DT, Murphy LJ, Lacson RG: Multihormonal regulation of insulin-like growth factor-binding protein-1 in rat H4IIE hepatoma cells: the dominant role of insulin. Endocrinology 1991; 128: 2693-701.
32. Conover CA, Divertie GD, Lee PD: Cortisol increases plasma insulin-like growth factor binding protein-1 in humans. Acta Endocrinol 1993; 128: 140-3.
33. Lee PDK, Conover CA, Powell DR: Regulation and function of insulin-like growth factor binding protein-1. Proc Soc Exp Biol Med 1993; 204: 4-29.
34. Price WA, Stiles AD, Moats-Staats BM, D'Ercole AJ: Gene expression of insulin-like growth factors (IGFs), the type I IGF receptor, and the IGF-binding proteins in dexamethasone-induced fetal growth retardation. Endocrinology 1992; 130: 1424-32.
35. Conover CA, Lee PD, Riggs BL, Powell DR: Insulin-like growth factor binding protein-1 expression in cultured human bone cells: regulation by insulin and glucocorticoids. Endocrinology 1996; 137: 3295-301.
36. Lee PD, Giudice LC, Conover CA, Powell DR: Insulin-like growth factor binding protein-1: recent findings and new directions. Proc Soc Exp Biol Med 1997; 216: 319-57.
37. Powell DR: Effects of renal failure on the growth hormone-insulin-like growth factor axis. J Pediatr 1997; 131(1 Pt 2): S13-6.
38. Murphy LJ, Rajkumar K, Molnar P: Phenotypic manifestations of insulin-like growth factor binding protein-1 (IGFBP-1) and IGFBP-3 overexpression in transgenic mice. Prog Growth Factor Res 1995; 6: 425-32.
39. Gutierrez-Ospina G, Calikoglu AS, Ye P, D'Ercole AJ: In vivo effects of insulin-like growth factor-I on the development of sensory pathways: analysis of the primary somatic sensory cortex (S1) of transgenic mice. Endocrinology 1996; 137: 5484-92.
40. Bernardini S, Cianfarani S, Spagnoli A, et al.: Expression and down-regulation by retinoic acid of IGF binding protein-2 and -4 in medium from human neuroblastoma cells. J Neuroendocrinol 1994; 6: 409-13.
41. Müller HL, Oh Y, Lehrnbecher T, Blum WF, Rosenfeld RG: Insulin-like growth factor-binding protein-2 concentrations in cerebrospinal fluid and serum of children with malignant solid tumors or acute leukemia. J Clin Endocrinol Metab 1994; 79: 428-34.
42. Russo VC, Bach LA, Fosang AJ, Baker NL, Werther GA: Insulin-like growth factor binding protein-2 binds to cell surface proteoglycans in the rat brain olfactory bulb. Endocrinology 1997; 138: 4858-67.
43. Arai T, Busby W Jr, Clemmons DR: Binding of insulin-like growth factor (IGF) I or II to IGF-binding protein-2 enables it to bind to heparin and extracellular matrix. Endocrinology 1996; 137: 4571-5.
44. Schwander J, Mary JL: The RIA for IGFBP-2 in man: a meagre catch? Growth Regul 1993; 3: 104-8.
45. Hardouin S, Gourmelen M, Noguiez P, et al.: Molecular forms of serum insulin-like growth factor (IGF)-binding proteins in man: relationships with growth hormone and IGFs and physiological significance. J Clin Endocrinol Metab 1989; 69: 1291-301.
46. Smith WJ, Underwood LE, Clemmons DR: Effects of caloric or protein restriction on insulin-like growth factor-I (IGF-I) and IGF-binding proteins in children and adults. J Clin Endocrinol Metab 1995; 80: 443-9.
47. Nickerson T, Pollak M, Huynh H: Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2, 3, 4, and 5. Endocrinology 1998; 139: 807-10.
48. Conover CA, Clarkson JT, Bale LK: Effect of glucocorticoid on insulin-like growth factor (IGF) regulation of IGF-binding protein expression in fibroblasts. Endocrinology 1995; 136: 1403-10.
49. Kanzaki S, Baxter RC, Knutsen R, Baylink DJ, Mohan S: Evidence that human bone cells in culture secrete insulin-like growth factor (IGF)-II and IGF binding protein-3 but not acid-labile subunit both under basal and regulated conditions. J Bone Miner Res 1995; 10: 854-8.
50. Paolisso G, Ammendola S, Del Buono A, et al.: Serum levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 in healthy centenarians: relationship with plasma leptin and lipid concentrations, insulin action, and cognitive function. J Clin Endocrinol Metab 1997; 82: 2204-9.
51. Juul A, Dalgaard P, Blum WF, et al.: Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab 1995; 80: 2534-42.
52. Gucev ZS, Oh Y, Kelley KM, Labarta JI, Vorwerk P, Rosenfeld RG: Evidence for insulin-like growth factor (IGF)-independent transcriptional regulation of IGF binding protein-3 by growth hormone in SKHEP-1 human hepatocarcinoma cells. Endocrinology 1997; 138: 1464-70.
53. Vaccarello MA, Diamond FB Jr, Guevara-Aguirre J, et al.: Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/ Laron syndrome. J Clin Endocrinol Metab 1993; 77: 273-80.
54. Kanety H, Karasik A, Klinger B, Silbergeld A, Laron Z: Long-term treatment of Laron type dwarfs with insulin-like growth factor-1 increases serum insulin-like growth factor-binding protein-3 in the absence of growth hormone activity. Acta Endocrinol 1993; 128:144-9.
55. Zapf J, Hauri C, Waldvogel M, et al.: Recombinant human insulin-like growth factor I induces its own specific carrier protein in hypophysectomized and diabetic rats. Proc Natl Acad Sci USA 1989; 86: 3813-7.
56. Lemmey AB, Glassford J, Flick-Smith HC, Holly JM, Pell JM: Differential regulation of tissue insulin-like growth factor-binding protein (IGFBP)-3, IGF-I and IGF type 1 receptor mRNA levels, and serum IGF-I and IGFBP concentrations by growth hormone and IGF-I. J Endocrinol 1997; 154: 319-28.
57. Conover CA, Clarkson JT, Durham SK, Bale LK: Cellular actions of insulin-like growth factor binding protein-3. In Current Directions in Insulin-like Growth Factor Research, edited by LeRoith D, Raizada MK, pp. 255-65. New York, Plenum Press 1994.
58. Olney RC, Wilson DM, Mohtai M, Fielder PJ, Smith RL: Interleukin-1 and tumor necrosis factor-alpha increase insulin-like growth factor-binding protein-3 (IGFBP-3) production and IGFBP-3 protease activity in human articular chondrocytes. J Endocrinol 1995; 146: 279-86.
59. Besset V, Le Magueresse-Battistoni B, Collette J, Benahmed M: Tumor necrosis factor alpha stimulates insulin-like growth factor binding protein 3 expression in cultured porcine Sertoli cells. Endocrinology 1996; 137: 296-303.
60. Oh Y, Müller HL, Ng L, Rosenfeld RG: Transforming growth factor-β-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J Biol Chem 1995; 270: 13589-92.
61. Han GR, Dohi DF, Lee HY, et al.: All-trans-retinoic acid increases transforming growth factor-beta2 and insulin-like growth factor binding protein-3 expression through a retinoic acid receptor-alpha-dependent signaling pathway. J Biol Chem 1997; 272: 13711-6.
62. Hayden JM, Strong DD, Baylink DJ, Powell DR, Sampath TK, Mohan S: Osteogenic protein-1 stimulates production of insulin-like growth factor binding protein-3 nuclear transcripts in human osteosarcoma cells. Endocrinology 1997; 138: 4240-7.
63. Huynh H, Yang YF, Pollak M: Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem 1996;271: 1016-21.
64. DiBattista JA, Dore S, Morin N, Abribat T: Prostaglandin E2 up-regulates insulin-like growth factor binding protein-3 expression and synthesis in human articular chondrocytes by a c-AMP-independent pathway: role of calcium and protein kinase A and C. J Cell Biochem 1996; 63: 320-33.
65. Buckbinder L, Talbott R, Velasco-Miguel S, et al.: Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995; 377: 646-9.
66. Jaques G, Noll K, Wegmann B, et al.: Nuclear localization of insulin-like growth factor binding protein 3 in a lung cancer cell line. Endocrinology 1997; 138: 1767-70.
67. Murphy LJ, Molnar P, Lu X, Huang H: Expression of human insulin-like growth factor-binding protein-3 in transgenic mice. J Mol Endocrinol 1995; 15: 293-303.
68. Oh Y, Müller HL, Lamson G, Rosenfeld RG: Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells: cell surface binding and growth inhibition. J Biol Chem 1993; 268: 14964-71.
69. Oh Y. IGF-independent regulation of breast cancer growth by IGF binding proteins. Breast Cancer Res Treatment 1998; 47: 283-93.
70. Gill ZP, Perks CM, Newcomb PV, Holly JM: Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. J Biol Chem 1997; 272: 25602-7.
71. Gucev ZS, Oh Y, Kelley KM, Labarta JI, Vorwerk P, Rosenfeld RG: Evidence for insulin-like growth factor (IGF)-independent transcriptional regulation of IGF binding protein-3 by growth hormone in SKHEP-1 human hepatocarcinoma cells. Endocrinology 1997; 138: 1464-70.
72. Hamon GA, Hunt TK, Spencer EM: In vivo effects of systemic insulin-like growth-I alone and complexed with insulin-like growth factor binding protein-3 on corticosteroid suppressed wounds. Growth Regul 1993; 3: 53-6.
73. Clark RG, Mortensen D, Reifsynder D, Mohler M, Etcheverry T, Mukku V: Recombinant human insulin-like growth factor binding protein-3 (rhIGFBP-3): effects on the glycemic and growth promoting activities of rhIGF-1 in the rat. Growth Regul 1993; 3: 50-2.
74. Weinzimer SA, Macarak E, Cohen P: The role of the IGF-IGFBP axis in the regulation of bladder smooth muscle growth [abstract]. In Program and Abstracts of the 80th Annual Meeting of The Endocrine Society (New Orleans, LA), pp. 316-7. Bethesda, MD, The Endocrine Society 1998.
75. Mandel SH, Moreland E, Rosenfeld RG, Gargosky SE: The effect of GH therapy on the immunoreactive forms and distribution of IGFBP-3, IGF-I, the acid-labile subunir, and growth rate in GH-deficient children. Endocrine 1997; 7: 351-60.
76. Rosenfeld RG, Attie KM, Frane J, et al.: Growth hormone therapy of Turner's syndrome: beneficial effect on adult height. J Pediatr 1998; 132: 319-24.
77. Grimberg A, Cohen P: Optimizing growth hormone therapy in children. Horm Res 1997; 48(suppl 5): 11-5.
78. Weinzimer SA, Homan SA, Ferry RJ, Moshang T: Serum IGF-I and IGFBP-3 concentrations do not accurately predict growth hormone deficiency in children with brain tumors. Clin Endocrinol (Oxf); 51: 339-45.
79. Kurland ES, Rosen CJ, Cosman F, et al.: Insulin-like growth factor-I in men with idiopathic osteoporosis. J Clin Endocrinol Metab 1997; 82: 2799-805.
80. Mohan S, Farley JR, Baylink DJ: Age-related changes in IGFBP-4 and IGFBP-5 levels in human serum and bone: implications for bone loss with aging. Prog Growth Factor Res 1995; 6: 465-73.
81. Mohan S, Libanati C, Dony C, Lang K, Srinivasan N, Baylink DJ: Development, validation, and application of a radioimmunoassay for insulin-like growth factor binding protein-5 in human serum and other biological fluids. J Clin Endocrinol Metab 1995; 80: 2638-45.
82. Mohan S, Nakao Y, Honda Y, et al.: Studies on the mechanisms by which insulin-like growth factor (IGF) binding protein-4 (IGFBP-4) and IGFBP-5 modulate IGF actions in bone cells. J Biol Chem 1995; 270: 20424-31.
83. Scharla SH, Strong DD, Mohan S, Baylink DJ, Linkhart TA: 1,25-Dihydroxyvitamin D3 differentially regulates the production of insulin-like growth factor I (IGF-I) and IGF-binding protein-4 in mouse osteoblasts. Endocrinology 1991; 129: 3139-46.
84. Andress DL, Birnbaum RS: Human osteoblast-derived insulin-like growth factor (IGF) binding protein-5 stimulates osteoblast mitogenesis and potentiates IGF action. J Biol Chem 1992; 267: 22467-72.
85. Baxter RC, Saunders H: Radioimmunoassay of insulin-like growth factor-binding protein-6 in human serum and other body fluids. J Endocrinol 1992; 134: 133-9.
86. Claussen M, Buergisser D, Schuller AG, Matzner U, Braulke T: Regulation of insulin-like growth factor (IGF)-binding protein-6 and mannose 6-phosphate/IGF-II receptor expression in IGF-IL-overexpressing NIH 3T3 cells. Mol Endocrinol 1995; 9: 902-12.
87. Blat C, Villaudy J, Binoux M: In vivo proteolysis of serum IGFBP-3 results in increased availability of IGF to target cells. J Clin Invest 1994; 93: 2286-90.
88. Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG: Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992; 75: 1046-53.
89. Rajah R, Bhala A, Nunn SE, Peehl DM, Cohen P: 7S nerve growth factor is an insulin-like growth factor binding protein protease. Endocrinology 1996; 137: 2676-82.
90. Angelloz-Nicoud P, Harel L, Binoux M: Recombinant human insulin-like growth factor (IGF) binding protein-3 stimulates prostate carcinoma cell proliferation via an IGF-dependent mechanism: role of serine proteases. Growth Regul 1996; 6: 130-6.
91. Zheng B, Clarke JB, Busby WH, Duan C, Clemmons DR: Insulin-like growth factor-binding protein-5 is cleaved by physiological concentrations of thrombin. Endocrinology 1998; 139: 1708-14.
92. Conover CA, DeLeon DD: Acid activated insulin-like growth factor binding protein-3 proteolysis in normal and transformed cells: role of cathepsin D. J Biol Chem 1994; 2691: 7076-80.
93. Conover CA, Perry JE, Tindall DJ: Endogenous cathepsin D-mediated hydrolysis of insulin-like growth factor-binding proteins in cultured human prostatic carcinoma cells. J Clin Endocrinol Metab 1995; 80: 987-93.
94. Nunn S, Peehl DM, Cohen P: Acid-activated insulin-like growth factor binding protein protease activity of cathepsin D in normal and malignant prostatic epithelial cells and seminal plasma. J Cell Physiol 1997; 171: 196-204.
95. Claussen M, Kubler B, Wendland M, et al.: Proteolysis of insulin-like growth factors (IGF) and IGF binding proteins by cathepsin D. Endocrinology 1997; 138: 3797-803.
96. Fowlkes JL, Suzuki K, Nagase H, Thrailkill KM: Proteolysis of insulin-like growth factor binding protein-3 during rat pregnancy: a role for matrix metalloproteinases. Endocrinology 1994; 135: 2810-3.
97. Fowlkes JL, Enghild JJ, Suzuki K, Nagase H: Matrix metalloproteinases degrade insulin-like growth factor binding protein-3 in dermal fibroblast cultures. J Biol Chem 1994; 269: 742-6.
98. Rajah R, Katz L, Nunn S, Solberg P, Beers T, Cohen P: Insulin-like growth factor binding protein proteases: functional regulators of cell growth. Prog Growth Factor Res 1996; 6: 273-84.
99. Bereket A, Wilson TA, Kolasa AJ, Fan J, Lang CH: Regulation of the insulin-like growth factor system by acute acidosis. Endocrinology 1996; 137: 2238-45.
100. Cohen P, Peehl DM, Graves HC, Rosenfeld RG: Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol 1994; 142: 407-15.
101. Noveral J, Bhala A, Grunstein M, Cohen P. The insulin-like growth factor axis in airway smooth muscle cells. Am J Physiol 1994; 267: L761-5.
102. 4 facilitates airway smooth muscle cell proliferation via modulation of the IGF axis. Am J Physiol 1995; 269(2 Pt 1): L151-7.
103. 4 induces MMP-1, which functions as an IGFBP protease in human airway smooth muscle cells. Am J Physiol 1996; 271(6 Pt 1): L1014-22.
104. Rajah R, Nachajon RV, Collins MH, Hakonarson H, Grunstein MM, Cohen P. Elevated levels of IGF-binding protein protease MMP-1 in asthmatic airway smooth muscle. Am J Resp Cell Mol Biol 1999; 20: 199-208.
105. Bereket A, Lang CH, Blethen SL, Fan J, Frost RA, Wilson TA: Insulin-like growth factor binding protein-3 proteolysis in children with insulin-dependent diabetes mellitus: a possible role for insulin in the regulation of IGFBP-3 protease activity. J Clin Endocrinol Metab 1995; 80: 2282-8.
106. Besnard N, Pisselet C, ZapfJ, Hornebeck W, Monniaux D, Monget P: Proteolytic activity is involved in changes in intrafollicular insulin-like growth factor binding protein levels during growth and atresia of ovine ovarian follicles. Endocrinology 1996; 137: 1599-607.
107. Fowlkes JL, Thrailkill KM, George-Nascimento C, Rosenberg CK, Serra DM: Heparin-binding, highly basic regions within the thyroglobulin type-1 repeat of insulin-like growth factor (IGF)-binding proteins (IGFBPs) -3, -5, and -6 inhibit IGFBP-4 degradation. Endocrinology 1997; 138: 2280-5.
108. Donnelly MJ, Holly JM: The role of IGFBP-3 in the regulation of IGFBP-4 proteolysis. J Endocrinol 1996; 149: R1-7.
109. Salahifar H, Baxter RC, Martin JL: Insulin-like growth factor binding protein (IGFBP)-3 protease activity secreted by MCF-7 breast cancer cells: inhibition by IGFs does not require IGF-IGFBP interaction. Endocrinology 1997; 138: 1683-90.
110. Li YM, Schacher DH, Liu Q, et al.: Regulation of myeloid growth and differentiation by the insulin-like growth factor I receptor. Endocrinology 1997; 138: 362-8.
111. Karas M, Danilenko M, Fishman D, LeRoith D, Levy J, Sharoni Y: Membrane-associated insulin-like growth factor-binding protein-3 inhibits insulin-like growth factor-I-induced insulin-like growth factor-I receptor signaling in ishikawa endometrial cancer cells. J Biol Chem 1997; 272: 16514-20.
112. Olney RC, Tsuchiya K, Wilson DM, et al.: Chondrocytes from osteoarthritic cartilage have increased expression of insulin-like growth factor I (IGF-I) and IGF-binding protein-3 (IGFBP-3) and -5, but not IGF-II or IGFBP-4. J Clin Endocrinol Metab 1996; 81: 1096-103.
113. Barreca A, Artini PG, Cesarone A, et al.: Interrelationships between follicle stimulating hormone and the growth hormone/insulin-like growth factor/IGF-binding proteins axes in human granulosa cells in cultur. J Endocrinol Invest 1996; 19: 35-42.
114. de la Sota RL, Simmen FA, Diaz T, Thatcher WW: Insulin-like growth factor system in bovine first-wave dominant and subordinate follicles. Biol Reprod 1996; 55: 803-12.
115. Hasegawa Y, Hasegawa T, Fujii K, et al.: High ratios of free to total insulin-like growth factor-I in early infancy. J Clin Endocrinol Metab 1997; 82: 156-8.
116. Wang J, Niu W, Witte DP, et al.: Overexpression of insulin-like growth factor-binding protein-4 (IGFBP-4) in smooth muscle cells of transgenic mice through a smooth muscle alpha-actin-IGFBP-4 fusion gene induces smooth muscle hypoplasia. Endocrinology 1998; 139: 2605-14.
117. Noll K, Wegmann B, Havemann K, Jaques G: Insulin-like growth factors stimulate the release of insulin-like growth factor-binding protein-3 (IGFBP-3) and degradation of IGFBP-4 in nonsmall cell lung cancer cell lines. J Clin Endocrinol Metab 1996; 81: 2653-62.
118. Jones JI, Clemmons DR: Insulin-like growth factors and their binding proteins: biological actions. Endocrinol Rev 1995; 16: 3-34.
119. Ranke MB, Elmlinger M: Functional role of insulin-like growth factor binding proteins. Horm Res 1997; 48(suppl 4): 9-15.
120. Cohen P, Lamson G, Okajima T, Rosenfeld RG: Transfection of the human insulin-like growth factor binding protein-3 gene into Balb/c fibroblasts inhibits cellular growth. Mol Endocrinol 1993; 7: 380-6.
121. Zadeh SM, Binoux M: The 16-kDa proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 inhibits the mitogenic action of fibroblast growth factor on mouse fibroblasts with a targeted disruption of the type 1 IGF receptor gene. Endocrinology 1997; 138: 3069-72.
122. Valentinis B, Bhala A, DeAngelis T, Baserga R, Cohen P: The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Mol Endocrinol 1995; 9: 361-7.
123. Gucev ZS, Oh Y, Kelley KM, Rosenfeld RG: Insulin-like growth factor binding protein 3 mediaties retinoic acid- and transforming growth factor β2-induced growth inhibition in human breast cancer cells. Cancer Res 1996; 56: 1545-50.
124. Erondu NE, Dake BL, Moser DR, Lin M, Boes M, Bar RS: Regulation of endothelial IGFBP-3 synthesis and secretion by IGF-I and TGF-beta. Growth Regul 1996; 6: 1-9.
125. Lalou C, Lassarre C, Binoux M: A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. Endocrinology 1996; 137: 3206-12.
126. Lalou C, Lassarre C, Binoux M: A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. Endocrinology 1996; 137: 3206-12.
127. Leal SM, Liu Q, Huang SS, Huang JS: The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein-3 receptor. J Biol Chem 1997; 272: 20572-6.
128. Schedlich LJ, Young TF, Firth SM, Baxter RC: Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells. J Biol Chem 1998; 273: 18347-52.
129. Wraight CJ, Liepe IJ, Werther GA: Intracellular localisation of insulin-like growth factor binding protein-3 during mitosis in human keratinocytes. In Program & Abstracts of the 4th International Symposium on Insulin-like Growth Factors (Tokyo, Japan), p. 139. Tokyo, Foundation for Growth Science 1997.
130. Jaques G, Noll K, Wegmann B, Witten S, Kogan E, Radulescu RT, et al.: Nuclear localization of insulin-like growth factor binding protein 3 in a lung cancer cell line. Endocrinology 1997; 138: 1767-70.
131. Hodgkinson S, Fowke P, Al Somai N, McQuoid M: Proteins in tissue extracts which bind insulin-like growth factor binding protein-3 (IGFBP-3). J Endocrinol 1995; 145: R1-6.
132. Yang YW-H, Yanagishita M, Rechler MM: Heparin inhibition of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human fibroblasts and rat glioma cells: role of heparan sulfate proteoglycans. Endocrinology 1996; 137: 4363-71.
133. Liu BR, Lee HY, Clifford JL, Kurie JM, Cohen P: Direct functional interactions between IGFBP-3 and RXR regulate gene expression and cellular apoptosis. "Hot Topics" session of the 81st Annual Meeting of the Endocrine Society (San Diego, CA), 1999.
134. Xu W, Murphy LJ: Interaction of IGFBP-3 with latent transforming growth factor-β binding protein-1 identified using the yeast two-hybrid system. In Program & Abstracts of the 80th Annual Meeting of The Endocrine Society (New Orleans, LA), p. 313, Bethesda, MD, The Endocrine Society 1998.
135. Schenker T, Trueb B: Down-regulated proteins of mesenchymal tumor cells. Exp Cell Res 1998; 239: 161-8.
136. Reeve JG, Guadano A, Xiong J, Morgan J, Bleehen NM: Diminished expression of insulin-like growth factor (IGF) binding protein-5 and activation of IGF-I-mediated autocrine growth in simian virus 40-transformed human fibroblasts. J Biol Chem 1995; 270: 135-42.
137. Spencer EM, Chan K: A 3-dimensional model for the insulin-like growth factor binding proteins (IGFBPs): supporting evidence using the structural determinants of the IGF binding site on IGFBP-3. Prog Growth Factor Res 1995; 6: 209-14.
138. Hashimoto R, Ono M, Fujiwara H, et al.: Binding sites and binding properties of binary and ternary complexes of insulin-like growth factor-II (IGF-II), IGF-binding protein-3, and acid-labile subunit. J Biol Chem 1997; 272: 27936-42.
139. Firth SM, Ganeshprasad U, Baxter RC: Structural determinants of ligand and cell-surface binding of insulin-like-growth factor-binding protein-3. J Biol Chem 1998; 273:2631-8.
140. Oh Y, Nagalla SR, Yamanaka Y, Kim H-S, Wilson E, Rosenfeld RG: Synthesis and characterization of insulin-like growth factor binding protein (IGFBP-7). J Biol Chem 1996; 271: 30322-5.
141. Murphy M, Pykett MJ, Harnish P, Zang KD, George DL: Identification and characterization of genes differentially expressed in meningiomas. Cell Growth Differ 1993; 4: 715-22.
142. Yamauchi T, Umeda F, Masakado M, Isaji M, Mizushima S, Nawata H: Purification and molecular cloning of prostacyclin-stimulating factor from serum-free conditioned medium of human diploid fibroblast cells. Biochem J 1994; 303: 591-8.
143. Akaogi K, Okabe Y, Funahashi K, et al.: Cell adhesion activity of a 30-kDa major secreted protein from human bladder carcinoma cells. Biochem Biophys Res Commun 1994; 198: 1046-53.
144. Burger AM, ZhangX, Li H, et al.: Down-regulation of T1A12/mac25, a novel insulin-like growth factor binding protein related gene, is associated with disease progression in breast carcinomas. Oncogene 1998; 16: 2459-67.
145. Kim H-S, Nagalla SR, Oh Y, Wilson E, Roberts CT Jr, Rosenfeld RG: Identification of a family of low-affinity insulin-like growth factor binding proteins (IGFBPs): characterization of connective tissue growth factor as a member of the IGFBP superfamily. Proc Natl Acad Sci USA 1997; 94: 12981-6.
146. Bradham DM, Igarashi A, Potter RL, Grotendorst GR: Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol 1991; 1114: 1285-94.
147. Martinerie C, Viegas-Pequignot E, Guenard I, et al.: Physical mapping of human loci homologous to the chicken nov protooncogene. Oncogene 1992; 7: 2529-34.
148. Jay P, Berge-Lefranc J, Marsollier C, Mejean C, Taviaux S, Berta P: The human growth factor-inducible immediate early gene, CYR61, maps to chromosome Ip. Oncogene 1997: 14: 1753-7.
149. Zumbrunn J, Trueb B: Primary structure of a putative serine protease specific for IGF-binding proteins. FEBS Lett 1996; 398: 187-92.
150. Lassalle P, Molet S, Janin A, et al.: ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem 1996; 271: 20458-64.
151. Yamanaka Y, Wilson EM, Rosenfeld RG, Oh Y: Inhibition of insulin receptor activation by insulin-like growth factor binding proteins. J Biol Chem 1997; 272: 30729-34.
152. Vorwerk P, Yamanaka Y, Spagnoli A, Oh Y, Rosenfeld RG: Insulin and IGF binding by IGFBP-3 fragments derived from proteolysis, baculovirus expression and normal human urine. J Clin Endocrinol 1998; 83: 1392-5.
153. Wilson EM, Oh Y, Rosenfeld RG: Generation and characterization of an IGFBP-7 antibody: identification of 31kD IGFBP-7 in human biological fluids and Hs578T human breast cancer conditioned media. J Clin Endocrinol Metab 1997; 82: 1301-3.
154. Damon SE, Haugk KL, Swisshelm K, Quinn LS: Developmental regulation of Mac25/insulin-like growth factor-binding protein-7 expression in skeletal myogenesis. Exp Cell Res 1997; 237: 192-5.
155. th Annual DSL International Scientific Meeting, edited by Rosenfeld RG, Lee PDK, pp. 142-53. Webster TX, DSL Press 1998.
156. Yang DH, Kim H-S, Wilson EM, Rosenfeld RG, Oh Y: Identification of glycosylated 38-kDa connective tissue growth factor (IGFBP-related protein 2) and proteolytic fragments in human biological fluids, and up-regulation of IGFBP-rP2 expression by TGF-beta in Hs578T human breast cancer cells. J Clin Endocrinol Metab 1998; 83: 2593-6.
157. Chevalier G, Yeger H, Martinerie C, et al.: novH: differential expression in developing kidney and Wilm's tumors. Amer J Pathol 1998; 152: 1563-75.
158. Nunn SE, Gibson TB, Rajah R, Cohen P: Regulation of prostate cell growth by the insulin-like growth factor binding proteins and their proteases. Endocrine 1997; 7: 115-8.
159. Gebauer G, Jager W, Lang N: mRNA expression of components of the insulin-like growth factor system in breast cancer cell lines, tissues, and metastatic breast cancer cells. Anticancer Res 1998; 18: 1191-5.
160. Hankinson SE, Willett WC, Colditz GA, et al.: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351: 1393-6.
161. Ng EH, Ji CY, Tan PH, Lin V, Soo KC, Lee KO: Altered serum levels of insulin-like growth-factor binding proteins in breast cancer patients. Ann Surg Oncol 1998; 5: 194-201.
162. Li SL, Goko H, Xu ZD, et al.: Expression of insulin-like growth factor (IGF)-II in human prostate, breast, bladder, and paraganglioma tumors. Cell Tissue Res 1998; 291: 469-79.
163. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X: Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 1999; 91: 151-6.
164. Damon SE, Maddison L, Ware JL, Plymate SR: Overexpression of an inhibitory insulin-like growth factor binding protein (IGFBP), IGFBP-4, delays onset of prostate tumor formation. Endocrinology 1998; 139: 3456-64.
165. Ziegler J: Exposures and habits early in life may influence breast cancer risk. J Natl Cancer Inst 1998; 90: 187-8.
166. Colditz GA: Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst 1998; 90: 814-23.
167. Grodstein F, Stampfer MJ, Colditz GA, et al.: Postmenopausal hormone therapy and mortality [see comments in N Engl J Med 1997; 336: 1821-2]. N Engl J Med 1997; 336: 1769-75.
168. Roy JA, Sawka CA, Pritchard KI: Hormone replacement therapy in women with breast cancer: do the risks outweigh the benefits? J Clin Oncol 1996; 14: 997-1006.